Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast [Yahoo! Finance]
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $30.00 price target on the stock.